AnaptysBio Inc - Company Profile
Powered by 
All the sales intelligence you need on AnaptysBio Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AnaptysBio Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AnaptysBio Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
AnaptysBio Inc (Anaptys) is focused on advancing innovative therapeutics in immunology. The company is developing immune cell-modulating antibodies, with a product pipeline of clinical and preclinical resources targeting autoimmune and inflammatory diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Anaptys is deeply invested in advancing its portfolio of novel therapeutics through its extensive R&D initiatives. As of December 2025, the company holds approximately 96 issued patents and 120 pending applications worldwide, including collaborations with GSK and licensed patents from Centessa Pharmaceuticals (UK) Ltd. The intellectual property portfolio supports Anaptys’ diverse product candidates, including Rosnilimab, ANB032, ANB033, ANB101 and 102, Imsidolimab, and Etokimab. With 72 dedicated employees focusing on research and development, Anaptys is committed to driving innovation in immunology and inflammatory diseases. In FY2025, the company invested US$135.9 million on its R&D activities, which as a percentage of revenue stood at 57.9%.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer